An Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Cohorts to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonistic Monoclonal Antibody) in Combination With Vanucizumab (Anti-Ang2 and Anti-VEGF Bi-Specific Monoclonal Antibody) in Patients With Metastatic Solid Tumors

Trial Profile

An Open-Label, Multicenter, Dose Escalation Phase Ib Study With Expansion Cohorts to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Therapeutic Activity of RO7009789 (CD40 Agonistic Monoclonal Antibody) in Combination With Vanucizumab (Anti-Ang2 and Anti-VEGF Bi-Specific Monoclonal Antibody) in Patients With Metastatic Solid Tumors

Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jun 2017

At a glance

  • Drugs RO 7009789 (Primary) ; Vanucizumab (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 16 Mar 2017 Planned End Date changed from 1 Jul 2018 to 18 Jul 2018.
    • 16 Mar 2017 Planned primary completion date changed from 1 Jul 2018 to 18 Jul 2018.
    • 01 Jun 2016 Planned End Date changed from 1 Dec 2017 to 1 Jul 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top